AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting

 
• By Alaric DeArment
AstraZeneca announced Phase III results from the AEGEAN trial of Imfinzi in neoadjuvant NSCLC • Source: Shutterstock

More from Clinical Trials

More from R&D